Morepen Laboratories shares zoom 10% as company launches Empamore, 'a game-changing treatment' for Type 2 Diabetes; check details

Following the announcement, shares of the company on Tuesday, March 18, zoomed as much as 9.7% to ₹47 apiece on the NSE.

"With India being the diabetes capital of the world and over 101 million people suffering from the disease, Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health," the company said in its press release.

Morepen added that it manufactures Empagliflozin (API) in its USFDA-approved facilities and already has European DMF. The launch of Empamore reflects Morepen’s 40 years of pharmaceutical excellence, providing a cost-effective alternative to leading brands while ensuring affordability without compromising quality.

European DMF (or EDMF) stands for European Drug Master File. It is a document containing confidential information about an active pharmaceutical ingredient (API) or finished drug dosage form. It is used to protect intellectual property while allowing applicants to take responsibility for the medicinal product.

• Empagliflozin (Empamore 10 mg/25 mg)

• Empagliflozin 12.5 mg with Metformin 500/1000 mg (Empamore M 500/1000 mg)

Empagliflozin is a globally recognised SGLT2 inhibitor, widely used for diabetes management.

The company added that with prediabetes cases in India rising to nearly 136 million and the diabetes market expected to grow at a CAGR of 10.9%, Morepen’s launch of Empamore comes at a crucial time to provide an affordable and effective solution.

Speaking on the launch, Ashutosh Sharma, V.P. of Sales & Marketing, Morepen Laboratories, said, “At Morepen, we are dedicated to democratising healthcare by making world-class treatments accessible to all. With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90% lower cost than existing brands, helping millions manage their condition effectively without financial strain. This aligns with our commitment to empower people to take charge of their health.”